AbbVie to buy Botox maker Allergan for $63 billion

The acquisition aims to diversify AbbVie beyond its top-selling drug Humira, which will soon lose patent protection






Leave a Reply

Your email address will not be published. Required fields are marked as *

*

This blog is kept spam free by WP-SpamFree.